

Note

Synthesis and antibacterial activity of 6-(5-phenyl-[1,3,4]thiadiazol-2-ylamino)-benzopyran-2-ones

Sagar A Mayekar & Vinata V Mulwad*

Department of Chemistry, The Institute of Science, 15, Madam Cama Road, Mumbai 400 032, India

E-mail: vinata_mulwad@hotmail.com

Received 16 October 2007; accepted (revised) 13 May 2008

6-Amino coumarins **1a-c** on treatment with carbon disulphide in presence of iodine in pyridine give 6-isothiocyanato coumarins **2a-c**. Condensation of the acid hydrazide with 6-isothiocyanato coumarins has resulted in the formation of 2-benzoyl-*N*-(2-oxo-2*H*-benzopyran-6-yl)hydrazinecarbothioamides **3a-f** which are cyclized to 6-(5-phenyl-[1,3,4]thiadiazol-2-ylamino)-benzopyran-2-ones **4a-f** using Conc. H₂SO₄. The structures of the compounds **2a-c**, **3a-f** and **4a-f** have been established on the basis of spectral and analytical data. All compounds have been screened for their antimicrobial activity and showed that the introduction of 1,3,4-thiadiazole show significant antibacterial activities.

Keywords: 6-Isothiocyanato coumarins, 1,3,4-thiadiazole, iodine, pyridine, acid hydrazide

During recent years there has been intense investigation of different classes of thiadiazole compounds, many of which are known to possess interesting biological properties such as anti-microbial¹⁻³, antituberculosis⁴, antiinflammatory⁵⁻⁷, anticonvulsant^{8,9}, antihypertensive^{10,11}, local anesthetic¹², anticancer^{13,14}, and hypoglycemic activities¹⁵. In addition, 1,3,4-thiadiazoles exhibit various biological activities possibly due to the presence of the -N=C-S moiety¹⁶. Nitrogen mustards synthesized from 6-aminocoumarins exhibit carcinogenic activity¹⁷. They are also known to possess antiviral¹⁸ activity and especially effective against HIV₁(ref. 19). The Schiff bases of 6-aminocoumarins have been reported to exhibit biological activities like antibacterial and antifungal²⁰ activities. The biological importance of 1,3,4-thiadiazole derivatives has prompted us to synthesize 1,3,4-thiadiazoles derived from 6-amino coumarins, which may have some of the biological activity.


Results and Discussion

For this purpose, 6-isothiocyanato coumarins **2a-c** being the starting material were prepared from 6-amino

coumarins **1a-c** treatment with carbon disulphide and iodine in pyridine. Structures **2a-c** were confirmed on the basis of spectral and analytical data. The IR spectrum of **2a** in KBr showed presence of bands at 2079 for -NCS and 1726 cm⁻¹ for >C=O of coumarin. The ¹H NMR spectrum of the same in CDCl₃ showed a singlet at δ 2.48 for three protons of methyl group at C₇. Doublet observed at δ 6.41 and 7.60 for C₃-H and C₄-H respectively at *J* = 9Hz. Singlet observed at δ 7.19 and 7.33 for C₈-H and C₅-H proton respectively. The ¹³C NMR spectrum showed signal at δ 18.9 for the methyl carbon at C₇, 160.0 for the carbonyl of coumarin ring and other signal at 152.3, 142.0, 139.6, 136.8, 127.2, 124.4, 118.7, 117.5, 117.1. The condensation of the acid hydrazide with 6-isothiocyanato coumarins resulted in the formation of 2-benzoyl-*N*-(2-oxo-2*H*-benzopyran-6-yl)hydrazinecarbothioamides **3a-f**. Compounds **3a-f** are cyclized to 6-(5-phenyl-[1,3,4]thiadiazol-2-ylamino)-benzopyran-2-ones **4a-f** (Scheme I) using Conc. H₂SO₄ as dehydrating agent. The IR spectrum of **4a** in KBr showed presence of bands at 3331 for NH stretching, 1716 cm⁻¹ for >C=O of coumarin. The ¹H NMR spectrum of the same in DMSO-*d*₆ showed a singlet at δ 2.39 for three protons of methyl group at C₇. Doublet observed at 6.42 and 8.04 for C₃-H and C₄-H respectively at *J* = 9Hz. Singlet observed at 7.34 for C₈-H proton. The multiplet were observed at δ 7.46-7.55 for three protons at C₃′, C₅′ and C₄′-H. Doublet observed at δ 7.82 for two protons of C₂′ and C₆′-H. Singlet at δ 8.28 for one proton of C₅′-H and broad singlet observed at 9.77 was observed for one proton of NH which is D₂O exchangeable. The disappearance of other two NH group proved the product formation. The ¹³C NMR spectrum of compound **4a** in DMSO-*d*₆ showed signal at δ 18.4 for one CH₃ carbon at C₇. Signal at δ 160.2 for >C=O of coumarin, signal at δ 165.9 and 158.1 for C₂ and C₅ of thiadiazole respectively and other signal at 149.8, 144.2, 139.7, 134.9, 129.3, 128.8, 126.7, 120.0, 118.3, 118.0, 117.1, 115.7. The disappearance of >C=S signal also proved the product formation.

Antimicrobial activity

All the synthesized compounds **2a-c**, **3a-f** and **4a-f** were screened for their antibacterial activity against



Scheme I

S. aureus, *S. typhi* and *E. coli* (Table I) by the drug diffusion method²¹. The zone of inhibition was measured in mm and was compared with standard drug. DMSO was used as a blank and streptomycin was used as antibacterial standard. All the compounds were tested at 100 µg/mL and 250 µg/mL concentration.

From the antimicrobial screening of the compounds it could observe that the introduction of 1,3,4-thiadiazole show significant antibacterial activities, also compound **3a-f** show comparable antibacterial activity.

Experimental Section

General: Melting points were taken in open capillaries and are uncorrected. Purity of the compounds was checked on TLC. IR spectra (ν in cm^{-1}) were recorded on a Perkin-Elmer FTIR, ^1H NMR on a 300 MHz JEOL NMR AL300 using TMS as standard and mass spectra on a Shimadzu GC-MS QP-2010. All the compounds gave satisfactory elemental analysis.

General procedure for the synthesis of 6-isothiocyanato coumarins 2a-c

A solution of 2.54 g of iodine (10 mmole) in 20 mL of carbon disulphide was added drop-wise to a

Table I — Antibacterial activity of compounds **2a-c**, **3a-f** and **4a-f**

Compd	Zone of inhibition in mm					
	<i>S. aureus</i>		<i>S. typhi</i>		<i>E. coli</i>	
	100µg	250µg	100µg	250µg	100µg	250µg
2a	-	9	11	12	12	13
2b	-	10	12	13	12	14
2c	-	9	-	10	-	11
3a	-	11	11	13	14	15
3b	12	13	14	15	14	16
3c	-	11	11	13	12	13
3d	11	12	13	15	16	17
3e	13	14	12	14	13	15
3f	11	12	13	14	12	14
4a	16	18	17	19	17	20
4b	17	19	15	16	18	20
4c	14	15	15	17	15	17
4d	15	16	18	20	18	20
4e	16	18	17	21	18	20
4f	15	17	14	16	15	18

Disc size: 6.35mm Standard: streptomycin
Duration: 24 hrs. resistant (11mm/less) Control: DMSO
intermediate (12-14mm)
sensitive (15mm/more)

suspension of 1.89 g of 6-amino coumarin (10 mmole) in 20 mL of pyridine at 0°C. The contents were stirred for 4.0 h at 0°C. The reaction-mixture was distilled until all traces of carbon disulphide and pyridine were removed. Residue was treated with excess of dil. HCl and the separated solid was filtered, dried and further purified by using silica gel column chromatography eluting with hexane and EtOAc.

2a: Mol. Formula $C_{11}H_7NO_2S$, m.p. 192-94, yield: 89%; IR (KBr): 3076, 3030, 2957 (-CH), 2079 (-NCS), 1726 (>C=O), 1624, 1550, 1131, 1103, 887, 836 cm^{-1} ; 1H NMR ($CDCl_3$, δ): 2.48 (s, 3H, C_7-CH_3), 6.41 (d, 1H, $J = 9Hz$, C_3-H), 7.19 (s, 1H, C_8-H), 7.33 (s, 1H, C_5-H), 7.60 (d, 1H, $J = 9Hz$, C_4-H); ^{13}C NMR ($CDCl_3$, δ): 18.9, 117.1, 117.5, 118.7, 124.4, 127.2, 136.8, 139.6, 142.0, 152.3, 160.0; Mass (m/z %): M^+ 217 (100), 189 (37), 160 (40), 131 (22), 117 (15), 102 (42), 89 (27), 77 (75), 63 (48).

2b: Mol. Formula $C_{12}H_9NO_2S$, m.p. 230-32, yield: 86%; IR (KBr): 3082, 3046, 2962 (-CH), 2114 (-NCS), 1734 (>C=O), 1620, 1261, 1095, 1024, 801 cm^{-1} ; 1H NMR ($CDCl_3$, δ): 2.33 (s, 3H, C_4-CH_3), 2.40 (s, 3H, C_7-CH_3), 6.22 (s, 1H, C_3-H), 7.11 (s, 1H, C_8-H), 7.33 (s, 1H, C_5-H); ^{13}C NMR ($CDCl_3$, δ): 18.6, 18.8, 115.5, 118.8, 118.9, 121.6, 127.1, 136.5, 139.5, 151.2, 151.8, 160.1; Mass (m/z %): M^+ 231 (100), 202 (44), 188 (10), 170 (18), 145 (15), 115 (21), 102 (8).

2c: Mol. Formula $C_{10}H_5NO_2S$, m.p. 184-86, yield: 88%; IR (KBr): 3085, 3063 (-CH), 2084 (-NCS), 1721 (>C=O), 1618, 1562, 1179, 1106, 888, 821 cm^{-1} ; 1H NMR ($CDCl_3$, δ): 6.48 (d, 1H, $J = 9Hz$, C_3-H),

7.24-7.40 (m, 3H, C_5 , C_7 and C_8-H), 7.64 (d, 1H, $J = 9Hz$, C_4-H); Mass (m/z %): M^+ 203 (100), 175 (48), 146 (12), 117 (8), 103 (6), 89 (13).

General procedure for the synthesis of 2-benzoyl-N-(2-oxo-2H-benzopyran-6-yl)hydrazinecarbothioamide **3a-f**

To the solution of 7.5 mmole of benzoic acid hydrazide or isoniazid in 30 mL of ethanol was added 7.5 mmole of the appropriate 6-isothiocyanato coumarins. The mixture was refluxed on water-bath for 3 h, excess of ethanol was removed by distillation. The solid product obtained on cooling was filtered and washed with water and recrystallized from ethanol.

3a: Mol. Formula $C_{18}H_{15}N_3O_3S$, m.p. 116-20, yield: 79%; IR (KBr): 3238 (-NH), 3061, 2968 (-CH), 1717, 1680 (>C=O), 1627, 1522, 1240, 1128, 1098, 828 cm^{-1} ; 1H NMR ($DMSO-d_6$, δ): 2.26 (s, 3H, C_7-CH_3), 6.39 (d, 1H, $J = 9Hz$, C_3-H), 7.29 (s, 1H, C_8-H), 7.44-7.60 (m, 4H, C_5 , C_3' , C_5' and $C_4'-H$), 7.95 (d, 2H, $J = 6Hz$, C_2' and $C_6'-H$), 8.05 (d, 1H, $J = 9Hz$, C_4-H), 9.63 (s, 1H, NH-exchangeable), 9.76 (s, 1H, NH-exchangeable), 10.57 (s, 1H, NH-exchangeable); ^{13}C NMR ($DMSO-d_6$, δ): 18.5, 115.9, 117.0, 118.3, 126.5, 127.3, 128.7, 132.3, 133.4, 143.2, 145.6, 152.4, 155.2, 160.8, 160.9, 181.2.

3b: Mol. Formula $C_{19}H_{17}N_3O_3S$, m.p. 173-75, yield: 80%; IR (KBr): 3258 (-NH), 3061, 2978 (-CH), 1702, 1685 (>C=O), 1624, 1524, 1249, 1160, 1051, 699 cm^{-1} ; 1H NMR ($DMSO-d_6$, δ): 2.38 (s, 6H, C_4 , C_7-

CH₃), 6.23 (s, 1H, C₃-H), 7.21 (s, 1H, C₈-H), 7.48 (t, 2H, *J* = 9Hz, C_{3'} & C_{5'}-H), 7.60 (t, 1H, *J* = 9Hz, C_{4'}-H), 7.76 (s, 1H, C₅-H), 7.80 (d, 2H, *J* = 9Hz, C_{2'} and C_{6'}-H), 9.68 (s, 1H, NH-exchangeable), 9.82 (s, 1H, NH-exchangeable), 10.62 (s, 1H, NH-exchangeable).

3c: Mol. Formula C₁₇H₁₃N₃O₃S, m.p. 125-27, yield: 82%; IR (KBr): 3258 (-NH), 3054, 2969 (-CH), 1727, 1690 (>C=O), 1629, 1529, 1255, 1168, 1041, 692 cm⁻¹; ¹H NMR (DMSO-*d*₆, δ): 6.48 (d, 1H, *J* = 9Hz, C₃-H), 7.34 (d, 1H, *J* = 9Hz, C₈-H), 7.49 (t, 2H, *J* = 6Hz, C_{3'} and C_{5'}-H), 7.60-7.86 (m, 5H, C₇, C₅, C_{2'}, C_{6'} and C_{4'}-H), 8.07 (d, 1H, *J* = 9Hz, C₄-H), 9.60 (s, 1H, NH-exchangeable), 9.74 (s, 1H, NH-exchangeable), 10.66 (s, 1H, NH-exchangeable).

3d: Mol. Formula C₁₇H₁₄N₄O₃S, m.p. 174-76, yield: 77%; IR (KBr): 3301, 3233 (-NH), 3047, 2978 (-CH), 1734, 1680 (>C=O), 1626, 1533, 1265, 1173, 1044, 798 cm⁻¹; ¹H NMR (DMSO-*d*₆, δ): 2.24 (s, 3H, C₇-CH₃), 6.41 (d, 1H, *J* = 9Hz, C₃-H), 7.29 (s, 1H, C₈-H), 7.66 (s, 1H, C₅-H), 7.84 (d, 2H, *J* = 6Hz, C_{2'} and C_{6'}-H), 8.08 (d, 1H, *J* = 9Hz, C₄-H), 8.75 (d, 2H, *J* = 6Hz, C_{3'} and C_{5'}-H), 9.95 (br, 2H, two NH-exchangeable), 10.89 (s, 1H, NH-exchangeable).

3e: Mol. Formula C₁₈H₁₆N₄O₃S, m.p. 189-91, yield: 79%; IR (KBr): 3307, 3228 (-NH), 2964 (-CH), 1715, 1678 (>C=O), 1624, 1560, 1261, 1095, 1022, 801 cm⁻¹; ¹H NMR (DMSO-*d*₆, δ): 2.37 (s, 6H, C₄, C₇-CH₃), 6.23 (s, 1H, C₃-H), 7.21 (s, 1H, C₈-H), 7.75 (s, 1H, C₅-H), 7.82 (d, 2H, *J* = 6Hz, C_{2'} and C_{6'}-H), 8.74 (d, 2H, *J* = 6Hz, C_{3'} and C_{5'}-H), 9.84 (s, 1H, NH-exchangeable), 9.95 (s, 1H, NH-exchangeable), 10.88 (s, 1H, NH-exchangeable).

3f: Mol. Formula C₁₆H₁₂N₄O₃S, m.p. 163-65, yield: 80%; IR (KBr): 3289, 3206 (-NH), 3082, 3030 (-CH), 1748, 1678 (>C=O), 1645, 1574, 1544, 1214, 820 cm⁻¹; ¹H NMR (DMSO-*d*₆, δ): 6.47 (d, 1H, *J* = 9Hz, C₃-H), 7.36 (d, 1H, *J* = 9Hz, C₈-H), 7.60 (d, 1H, *J* = 9Hz, C₇-H), 7.72 (s, 1H, C₅-H), 7.84 (d, 2H, *J* = 6Hz, C_{2'} and C_{6'}-H), 8.07 (d, 1H, *J* = 9Hz, C₄-H), 8.76 (d, 2H, *J* = 6Hz, C_{3'} and C_{5'}-H), 9.99 (br, 2H, two NH-exchangeable), 10.90 (s, 1H, NH-exchangeable).

General procedure for the synthesis of 6-(5-phenyl-[1,3,4]thiadiazol-2-ylamino)-benzopyran-2-ones 4a-f

To 1 mmole of appropriate acid carbazide was added concentrated sulphuric acid (1 mL) drop-wise. The mixture was stirred at room temperature for 3 h. The reaction-mixture was poured into ice-water mixture. The solid product obtained was filtered and

washed with aqueous sodium carbonate solution followed by water and recrystallized from ethanol.

4a: Mol. Formula C₁₈H₁₃N₃O₂S, m.p. 196-98, yield: 74%; IR (KBr): 3331 (-NH), 3040 (-CH), 1716 (>C=O), 1630, 1563, 1497, 1420, 1119, 750 cm⁻¹; ¹H NMR (DMSO-*d*₆, δ): 2.39 (s, 3H, C₇-CH₃), 6.42 (d, 1H, *J* = 9Hz, C₃-H), 7.34 (s, 1H, C₈-H), 7.48 (m, 3H, C_{3'}, C_{5'} and C_{4'}-H), 7.82 (d, 2H, *J* = 6Hz, C_{2'} and C_{6'}-H), 8.04 (d, 1H, *J* = 9Hz, C₄-H), 8.28 (s, 1H, C₅-H), 9.77 (s, 1H, NH-exchangeable); ¹³C NMR (DMSO-*d*₆, δ): 18.4, 115.7, 117.1, 118.0, 118.3, 120.0, 126.7, 128.8, 129.3, 134.9, 139.7, 144.2, 149.8, 158.1, 160.2, 165.9.

4b: Mol. Formula C₁₉H₁₅N₃O₂S, m.p. 243-46, yield: 76%; IR (KBr): 3310 (-NH), 3050, 2978 (-CH), 1699 (>C=O), 1624, 1569, 1493, 1420, 1384, 1263, 1181, 1054, 886, 753, 684 cm⁻¹; ¹H NMR (DMSO-*d*₆, δ): 2.40 (s, 6H, C₄, C₇-CH₃), 6.37 (s, 1H, C₃-H), 7.33 (s, 1H, C₈-H), 7.48 (m, 3H, C_{3'}, C_{5'} and C_{4'}-H), 7.83 (d, 2H, *J* = 9Hz, C_{2'} and C_{6'}-H), 8.36 (s, 1H, C₅-H), 9.79 (s, 1H, NH-exchangeable); Mass (*m/z* %): M⁺ 349 (100), 334 (12), 316 (18), 246 (50), 231 (21), 213 (29), 189 (32), 160 (22), 118 (23), 103 (21), 91 (16), 77 (24).

4c: Mol. Formula C₁₇H₁₁N₃O₂S, m.p. 185-87, yield: 75%; IR (KBr): 3321 (-NH), 3046, 2976 (-CH), 1690 (>C=O), 1628, 1578, 1502, 1429, 1367, 1255, 1171, 1040, 888, 745, 678 cm⁻¹; ¹H NMR (DMSO-*d*₆, δ): 6.46 (d, 1H, *J* = 9Hz, C₃-H), 7.40 (d, 1H, *J* = 9Hz, C₈-H), 7.48 (m, 3H, C_{3'}, C_{5'} and C_{4'}-H), 7.60 (d, 1H, *J* = 9Hz, C₇-H), 7.83 (d, 2H, *J* = 6Hz, C_{2'} & C_{6'}-H), 8.08 (d, 1H, *J* = 9Hz, C₄-H), 8.24 (s, 1H, C₅-H), 9.76 (s, 1H, NH-exchangeable).

4d: Mol. Formula C₁₇H₁₂N₄O₂S, m.p. 234-36, yield: 68%; IR (KBr): 3311 (-NH), 3055, 2960 (-CH), 1696 (>C=O), 1622, 1567, 1486, 1420, 1368, 1245, 1163, 1054, 871, 765, 660 cm⁻¹; ¹H NMR (DMSO-*d*₆, δ): 2.37 (s, 3H, C₇-CH₃), 6.41 (d, 1H, *J* = 9Hz, C₃-H), 7.34 (s, 1H, C₈-H), 7.73 (d, 2H, *J* = 6Hz, C_{2'} and C_{6'}-H), 8.05 (d, 1H, *J* = 9Hz, C₄-H), 8.27 (s, 1H, C₅-H), 8.75 (d, 2H, *J* = 6Hz, C_{3'} and C_{5'}-H), 9.82 (s, 1H, NH-exchangeable).

4e: Mol. Formula C₁₈H₁₄N₄O₂S, m.p. 255-57, yield: 71%; IR (KBr): 3297 (-NH), 3049, 2970 (-CH), 1700 (>C=O), 1633, 1549, 1488, 1428, 1364, 1244, 1180, 1025, 876, 755, 679 cm⁻¹; ¹H NMR (DMSO-*d*₆, δ): 2.38 (s, 6H, C₄, C₇-CH₃), 6.35 (s, 1H, C₃-H), 7.32 (s, 1H, C₈-H), 7.74 (d, 2H, *J* = 6Hz, C_{2'} and C_{6'}-H), 8.35 (s, 1H, C₅-H), 8.75 (d, 2H, *J* = 6Hz, C_{3'} and C_{5'}-H), 9.80 (s, 1H, NH-exchangeable).

4f: Mol. Formula $C_{16}H_{10}N_4O_2S$, m.p. 219-21, yield: 70%; IR (KBr): 3311 (-NH), 3059, 2969 (-CH), 1696 ($>C=O$), 1646, 1585, 1497, 1433, 1345, 1225, 1146, 1036, 868, 735, 669 cm^{-1} ; 1H NMR (DMSO- d_6 , δ): 6.45 (d, 1H, $J = 9Hz$, $C_{3'-H}$), 7.40 (d, 1H, $J = 9Hz$, $C_{8'-H}$), 7.60 (d, 1H, $J = 9Hz$, $C_{7'-H}$), 7.75 (d, 2H, $J = 6Hz$, $C_{2''}$ and $C_{6''-H}$), 8.08 (d, 1H, $J = 9Hz$, $C_{4'-H}$), 8.23 (s, 1H, $C_{5'-H}$), 8.74 (d, 2H, $J = 6Hz$, $C_{3''}$ and $C_{5''-H}$), 9.83 (s, 1H, NH-exchangeable).

Acknowledgement

Authors are thankful to IIT, Mumbai for elemental analysis, Haffkine Institute Parel, Mumbai for biological testing.

References

- Desai K & Baxi A J, *Indian J Pharma Sci*, 54, **1992**, 183.
- Gawande N G & Shingare M S, *Indian J Chem*, 26B, **1987**, 387.
- Mamolo M G, Vio L & Banfi E, *Farmaco*, 51, **1996**, 71.
- Elcin E O, Sevim R, Fatma K, Nathaly S & Anatholy S D, *J Med Chem*, 47, **2004**, 6760.
- Mullican M D, Wilson M W, Connor D T, Kostlan C R, Schrier D J & Dyer R D, *J Med Chem*, 36, **1993**, 1090.
- Song Y, Connor D T, Sercel A D, Sorenson R J, Doubleday R, Unangst P C, Roth B D, Beylin V G, Gilbertsen R B, Chan K, Schrier D J, Guglietta A, Bornemeier D A & Dyer R D, *J Med Chem*, 42, **1999**, 1161.
- Labanausks L, Kalcas V, Udrenaite E, Gaidelis P, Brukstus A & Dauksas A, *Pharmazie*, 56, **2001**, 617.
- Chapleo C B, Myers M, Myers P L, Saville J F, Smith A C, Stillings M R, Tulloch I F, Walter D S & Welbourn A P, *J Med Chem*, 29, **1986**, 2273.
- Chapleo C B, Myers P L, Smith A C, Stillings M R, Tulloch I F & Walter D S, *J Med Chem*, 31, **1988**, 7.
- Turner S, Myers M, Gadie B, Nelson A J, Pape R, Saville J F, Doxey J C & Berridge T L, *J Med Chem*, 31, **1988**, 902.
- Turner S, Myers M, Gadie B, Hele S A, Horsley A, Nelson A J, Pape R, Saville J F, Doxey J C & Berridge T L, *J Med Chem*, 31, **1988**, 907.
- Mazzone G, Pignatello R, Mazzone S, Panico A, Penisi G, Castana R & Mazzone P, *Farmaco*, 48, **1993**, 1207.
- Miyamoto K, Koshiura R, Mori M, Yokoi H, Mori C, Hasegawa T & Takatori K, *Chem Pharm Bul*, 33, **1985**, 5126.
- Chou J Y, Lai S Y, Pan S L, Jow G M, Chern J W & Guh J H, *Biochem Pharmacol*, 66, **2003**, 115.
- Hanna M A, Girges M M, Rasala D & Gawinecki R, *Drug Res*, 45, **1995**, 1074.
- Holla B S, Poorjary N K, Rao S B & Shivananda M K, *Eur J Med Chem*, 37, **2002**, 511.
- Elderfield C R & Roy J, *J Med Chem*, 10, **1967**, 918.
- Kun E & Aurelian L, *US Pat* 412 783, **1991**; *Chem Abstr*, 115, **1991**, 92071t.
- Kun E (Octamer Inc USA) *PCT Int App*, WO9851, 307.
- Mulwad V V & Shirodkar J M, *Indian J Heterocycl Chem*, 11, **2002**, 199.
- Frankle S, Reitman S & Sonnenwirth A C, *Gradwol's Clinical Laboratory Method and Diagnosis*, 7th edn, Vol 2 (C V Mosby Co, Germany), **1970**, 1406.